Niesvizky, Ruben

Publications

Sort by

Co-Author Network

selected publications

Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia. 2023 GET IT
Publisher Correction: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. Communications biology. 2023 Article GET IT
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. Communications biology. 2022 Academic Article GET IT
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Frontiers in oncology. 2022 Review GET IT
Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis. Blood advances. 2022 Academic Article GET IT
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet. Haematology. 2022 Review GET IT
Times cited: 22
Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide. The Journal of pharmacology and experimental therapeutics. 2021 Academic Article GET IT
Times cited: 2
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. American journal of hematology. 2021 Academic Article GET IT
Times cited: 1
Prediction of Long Bone Fractures in Multiple Myeloma Patients in an Advanced Imaging World. The Israel Medical Association journal : IMAJ. 2021 Academic Article GET IT
Times cited: 1
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood cancer journal. 2021 Academic Article GET IT
Times cited: 11
Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem. 2021 Academic Article GET IT
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. Blood advances. 2021 Academic Article GET IT
Times cited: 5
Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function. Frontiers in cell and developmental biology. 2020 Academic Article GET IT
Times cited: 3
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. American journal of hematology. 2020 Academic Article GET IT
Times cited: 2
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood advances. 2020 Academic Article GET IT
Times cited: 13
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood cancer discovery. 2020 Academic Article GET IT
Times cited: 6
Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis. 2020 GET IT
Times cited: 1
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood cancer discovery. 2020 Academic Article GET IT
Times cited: 37
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA: a cancer journal for clinicians. 2020 Academic Article GET IT
Times cited: 12
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. medRxiv : the preprint server for health sciences. 2020 Article GET IT
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia & lymphoma. 2020 Academic Article GET IT
Times cited: 4
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological oncology. 2020 Academic Article GET IT
Times cited: 12
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. Blood cancer journal. 2020 Academic Article GET IT
Times cited: 11
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American journal of hematology. 2020 Academic Article GET IT
Times cited: 12
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. American journal of hematology. 2019 Academic Article GET IT
Times cited: 19
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone marrow transplantation. 2019 Academic Article GET IT
Times cited: 17
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2019 Academic Article GET IT
Times cited: 17
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. Clinical lymphoma, myeloma & leukemia. 2019 Academic Article GET IT
Times cited: 42
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019 Academic Article GET IT
Times cited: 84
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood advances. 2019 Academic Article GET IT
Times cited: 12
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. American journal of hematology. 2019 Academic Article GET IT
Times cited: 4
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood cancer journal. 2019 Academic Article GET IT
Times cited: 29
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019 Academic Article GET IT
Times cited: 37
Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leukemia & lymphoma. 2019 Letter GET IT
Times cited: 2
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood. 2018 Academic Article GET IT
Times cited: 26
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia & lymphoma. 2018 Academic Article GET IT
Times cited: 23
Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer research. 2018 Academic Article GET IT
Times cited: 44
High-Cutoff Hemodialysis in Myeloma Cast Nephropathy. JAMA. 2017 Editorial Article GET IT
Times cited: 1
Advances in immunotherapy in multiple myeloma. Current opinion in oncology. 2017 Review GET IT
Times cited: 13
Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 12
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 5
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical lymphoma, myeloma & leukemia. 2017 Academic Article GET IT
Times cited: 8
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. The Lancet. Oncology. 2017 Academic Article GET IT
Times cited: 281
IgM myeloma: A multicenter retrospective study of 134 patients. American journal of hematology. 2017 Academic Article GET IT
Times cited: 36
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. The Journal of clinical investigation. 2017 Academic Article GET IT
Times cited: 6
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood cancer journal. 2017 Academic Article GET IT
Times cited: 51
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 18
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 8
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. British journal of haematology. 2017 Academic Article GET IT
Times cited: 50
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2016 Academic Article GET IT
Times cited: 51
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. Journal of clinical pharmacology. 2016 Academic Article GET IT
Times cited: 10
Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma. 2016 GET IT
Times cited: 3
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 65
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. British journal of haematology. 2016 Academic Article GET IT
Times cited: 18
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Academic Article GET IT
Times cited: 103
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2016 Academic Article GET IT
Times cited: 56
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. British journal of haematology. 2016 Academic Article GET IT
Times cited: 27
Pulmonary hypertension complicating multiple myeloma. 2015 GET IT
Times cited: 11
Clinical characteristics of patients with relapsed multiple myeloma. Cancer treatment reviews. 2015 Review GET IT
Times cited: 29
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 125
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 55
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leukemia & lymphoma. 2015 Letter GET IT
Times cited: 3
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 1033
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 232
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014 Academic Article GET IT
Times cited: 173
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 8
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leukemia research. 2014 Review GET IT
Times cited: 17
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Review GET IT
Times cited: 296
[Living medicine: the patient, tie and cock]. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 2014 Editorial Article GET IT
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2013 Review GET IT
Times cited: 195
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British journal of haematology. 2013 Academic Article GET IT
Times cited: 78
IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2013 Academic Article GET IT
Times cited: 22
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Academic Article GET IT
Times cited: 122
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013 Academic Article GET IT
Times cited: 272
How lenalidomide is changing the treatment of patients with multiple myeloma. Critical reviews in oncology/hematology. 2013 Review GET IT
Times cited: 23
Immunomodulatory agents changing the landscape of multiple myeloma treatment. Critical reviews in oncology/hematology. 2013 Article GET IT
Times cited: 3
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 73
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 30
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013 Academic Article GET IT
Times cited: 133
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 19
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Academic Article GET IT
Times cited: 31
Treatment of multiple myeloma with carfilzomib in patients with renal injury. Clinical advances in hematology & oncology : H&O. 2013 Comment GET IT
Times cited: 2
Sustained disease control in transplant-ineligible patients: the role of continuous therapy. Leukemia research. 2012 Academic Article GET IT
Times cited: 2
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Academic Article GET IT
Times cited: 51
Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ case reports. 2012 Academic Article GET IT
Times cited: 22
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012 Academic Article GET IT
Times cited: 68
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. Cancer treatment reviews. 2012 Review GET IT
Times cited: 18
Novel therapies in monoclonal gammopathies. Hematology (Amsterdam, Netherlands). 2012 Review GET IT
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012 Review GET IT
Times cited: 119
IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 Review GET IT
Times cited: 175
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2011 Review GET IT
Times cited: 203
A single-dose conformal delivery of radiotherapy following osteoplasty : a novel approach to treatment of osteolytic metastasis in the setting of multiple myeloma. 2011 GET IT
Times cited: 8
Necrotizing soft tissue infection in two patients with multiple myeloma. 2011 GET IT
Times cited: 3
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 81
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. 2011 GET IT
Times cited: 251
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Review GET IT
Times cited: 325
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2010 Academic Article GET IT
Times cited: 115
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American journal of hematology. 2010 Academic Article GET IT
Times cited: 45
Monoclonal gammopathy of undetermined significance: a consensus statement. British journal of haematology. 2010 Conference Paper GET IT
Times cited: 99
Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant. Oncology (Williston Park, N.Y.). 2010 Academic Article GET IT
Times cited: 7
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010 Academic Article GET IT
Times cited: 129
Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. Journal of the National Comprehensive Cancer Network : JNCCN. 2010 Academic Article GET IT
Times cited: 19
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clinic proceedings. 2010 Comment GET IT
Times cited: 2
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer immunity. 2010 Academic Article GET IT
Times cited: 38
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 53
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 209
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Academic Article GET IT
Times cited: 345
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Academic Article GET IT
Times cited: 181
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Conference Paper GET IT
Times cited: 183
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. 2009 GET IT
Times cited: 132
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. British journal of haematology. 2009 Academic Article GET IT
Times cited: 72
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009 Review GET IT
Times cited: 395
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leukemia & lymphoma. 2009 Academic Article GET IT
Times cited: 65
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European journal of haematology. 2009 Academic Article GET IT
Times cited: 105
CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells. Journal of immunology (Baltimore, Md. : 1950). 2009 Academic Article GET IT
Times cited: 35
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 286
Novel agents in myeloma: an exciting saga. Cancer. 2009 Academic Article GET IT
Times cited: 6
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert opinion on investigational drugs. 2009 Review GET IT
Times cited: 19
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 43
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 89
Aspirin as thromboprophylaxis in myeloma. Leukemia & lymphoma. 2008 Letter GET IT
Times cited: 2
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 97
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 100
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 Academic Article GET IT
Times cited: 59
Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11. The Journal of biological chemistry. 2008 Academic Article GET IT
Times cited: 104
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 15
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in hematology. 2008 Review GET IT
Times cited: 16
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 66
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 35
Re: When you look matters: the effect of assessment schedule on progression-free survival. Journal of the National Cancer Institute. 2008 Letter GET IT
Times cited: 7
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. 2007 GET IT
Times cited: 722
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 55
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2007 Letter GET IT
Times cited: 112
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. The New England journal of medicine. 2007 Academic Article GET IT
Times cited: 1122
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2007 Academic Article GET IT
Times cited: 164
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clinical advances in hematology & oncology : H&O. 2007 Conference Paper GET IT
Times cited: 5
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. British journal of haematology. 2007 Academic Article GET IT
Times cited: 82
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer research. 2006 Academic Article GET IT
Times cited: 194
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006 Academic Article GET IT
Times cited: 34
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer research. 2005 Academic Article GET IT
Times cited: 93
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Academic Article GET IT
Times cited: 105
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 145
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 167
Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer research. 2005 Academic Article GET IT
Times cited: 61
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005 Academic Article GET IT
Times cited: 168
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British journal of haematology. 2004 Academic Article GET IT
Times cited: 672
Kyphoplasty enhances function and structural alignment in multiple myeloma. Clinical orthopaedics and related research. 2004 Academic Article GET IT
Times cited: 86
Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease. Seminars in oncology. 2003 Review GET IT
Times cited: 25
Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Seminars in oncology. 2003 Academic Article GET IT
Times cited: 53
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 64
Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 7
Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 2
Extensive bone marrow necrosis associated with multiple myeloma. Leukemia. 1999 Letter GET IT
Times cited: 4
Epstein-Barr virus-associated lymphoma after treatment of macroglobulinemia with cladribine. The New England journal of medicine. 1999 Letter GET IT
Times cited: 11
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer. 1999 Review GET IT
Times cited: 383
Pathophysiology and management of bone disease in multiple myeloma. Cancer investigation. 1997 Review GET IT
Times cited: 10
Proteinaceous (angiocentric sclerosing) lymphadenopathy: a polyclonal systemic, nonamyloid deposition disorder. 1995 GET IT
Times cited: 9
Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. British journal of haematology. 1995 Academic Article GET IT
Times cited: 40
von Willebrand factor binding to collagen in patients with end-stage renal disease. The Journal of laboratory and clinical medicine. 1994 Academic Article GET IT
Times cited: 8
Biology and treatment of multiple myeloma. Blood reviews. 1993 Review GET IT
Times cited: 52
2-Chlorodeoxyadenosine for multiple myeloma. Blood. 1993 Letter GET IT
Times cited: 9
Proto-oncogene analysis in multiple myeloma. The American journal of pathology. 1992 Academic Article GET IT
Times cited: 14

more ...

less ...

Background

education and training

M.D., National Autonomous University of Mexico, Faculty of Medicine (Mexico) 1985

Contact

full name

Ruben Niesvizky

primary email

run9001@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Ruben Niesvizky Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage